Elanco Launches New Anti-IL-31 Monoclonal Antibody for Dogs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: PRnewswire
- Product Launch: Elanco Animal Health has officially launched Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis, marking an expansion in the company's dermatology portfolio.
- Market Timing: The launch coincides with an anticipated longer and more intense allergy season across the country, which is expected to exacerbate issues for nearly two-thirds of itchy dogs, significantly increasing the demand for Befrena.
- Efficacy Advantage: Befrena begins controlling allergic itch within 24 hours by neutralizing IL-31, a key cytokine, and offers a convenient 6 to 8 weeks dosing interval, greatly enhancing convenience and efficacy for veterinarians and pet owners.
- Strategic Implications: The introduction of this product not only enriches Elanco's treatment options but also strengthens its competitive position in the veterinary pharmaceuticals market, addressing the growing demand for pet health solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.980
Low
22.00
Averages
25.50
High
30.00
Current: 23.980
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elanco Launches New Anti-IL-31 Monoclonal Antibody for Dogs
- Product Launch: Elanco Animal Health has officially launched Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis, marking an expansion in the company's dermatology portfolio.
- Market Timing: The launch coincides with an anticipated longer and more intense allergy season across the country, which is expected to exacerbate issues for nearly two-thirds of itchy dogs, significantly increasing the demand for Befrena.
- Efficacy Advantage: Befrena begins controlling allergic itch within 24 hours by neutralizing IL-31, a key cytokine, and offers a convenient 6 to 8 weeks dosing interval, greatly enhancing convenience and efficacy for veterinarians and pet owners.
- Strategic Implications: The introduction of this product not only enriches Elanco's treatment options but also strengthens its competitive position in the veterinary pharmaceuticals market, addressing the growing demand for pet health solutions.
See More
Elanco to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Elanco Animal Health will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference on May 27, featuring CEO Jeff Simmons and CFO Bob VanHimbergen, showcasing the company's leadership in animal health.
- Key Speaking Engagements: On June 2, Jeff Simmons will present at the William Blair 46th Annual Growth Stock Conference, further elaborating on the company's strategic direction and market outlook, which is expected to attract significant investor interest.
- Live Streaming and Replays: The events will feature live audio webcasts available on Elanco's investor website under the
See More
Elanco Animal Health Q1 2026 Earnings Call Insights
- Significant Growth: Elanco achieved a 10% organic constant currency revenue growth in Q1 2026, with revenues reaching $1.371 billion, exceeding market expectations and demonstrating the company's continued market share expansion in the pet health sector, thereby enhancing confidence in future growth.
- Innovation-Driven Revenue: The company's innovation products contributed $287 million in revenue during the first quarter, with the full-year innovation revenue target raised to $1.2 billion, indicating that Elanco's ongoing investment in product innovation will provide a long-term competitive advantage.
- Optimistic Financial Outlook: Elanco has raised its full-year organic constant currency growth expectation to 5% to 7%, alongside an adjusted EBITDA forecast increase to $975 million to $1.005 billion, reflecting management's confidence in future performance and strong market demand.
- Debt Management Strategy: The company has improved its year-end net leverage target to 3.0x to 3.2x, indicating a priority on managing free cash flow, while continuing to focus on debt repayment and small tuck-in acquisition opportunities to enhance financial flexibility.
See More
Elanco Raises Full Year Outlook and Innovation Targets
- Strong Financial Performance: In Q1 2026, Elanco reported total revenue of $1.371 billion, a 15% increase year-over-year, with Pet Health revenue reaching $710 million, up 12%, showcasing the company's robust performance under its innovation-led strategy.
- Innovation-Driven Growth: The successful launches of new products like Zenrelia and Credelio Quattro have driven market share gains, particularly in the Pet Health and Farm Animal segments, which achieved revenue growth of 12% and 18% respectively, indicating the company's competitive edge in the market.
- Significant EBITDA Improvement: Adjusted EBITDA for Q1 was $334 million, reflecting a 21% increase compared to the previous year, highlighting ongoing improvements in cost control and operational efficiency, which further bolster investor confidence.
- Upgraded Full-Year Guidance: Elanco has raised its full-year revenue outlook for 2026 to between $5.010 billion and $5.085 billion, anticipating benefits from favorable foreign exchange rates and continued price growth, demonstrating the company's agility in a dynamic market environment.
See More
Elanco to Announce Q1 Earnings on May 6
- Earnings Announcement Date: Elanco (ELAN) is set to announce its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.34, reflecting an 8.1% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: Analysts project Elanco's Q1 revenue to reach $1.28 billion, representing a 7.6% year-over-year increase, indicating sustained demand and strategic market expansion in the animal health sector.
- Performance Beat Record: Over the past two years, Elanco has beaten EPS and revenue estimates 88% of the time, showcasing its stable performance and management capabilities, which may bolster investor confidence in future results.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and seven downward adjustments, while revenue estimates experienced three upward revisions and two downward adjustments, reflecting mixed market perceptions regarding the company's future performance.
See More
Elanco Secures FDA Emergency Use Authorization for Screwworm Treatment
- Emergency Use Authorization: Elanco has received Emergency Use Authorization from the FDA for Negasunt Powder, allowing its use for the prevention and treatment of New World screwworm infestations, ensuring veterinarians and livestock producers have immediate access to effective treatment options should the pest be detected in the U.S.
- EPA Exemption Support: Additionally, Elanco has secured a Section 18 Emergency Exemption from the EPA for Tanidil, enabling its use in various livestock species, which will enhance the livestock industry's ability to respond to potential infestations.
- Distribution Channels: Negasunt Powder and Tanidil will be distributed through the U.S. Animal Plant Health Inspection Service (APHIS) and its National Veterinary Stockpile, ensuring timely access to necessary medications for producers to mitigate economic losses in the event of an infestation.
- Education and Prevention Measures: Elanco emphasizes the importance of self-education for producers regarding New World screwworm prevention and encourages regular livestock inspections to facilitate early detection and treatment, thereby reducing tissue damage and mortality rates.
See More
Elanco Launches New Anti-IL-31 Monoclonal Antibody for Dogs
- Product Launch: Elanco Animal Health has officially launched Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis, marking an expansion in the company's dermatology portfolio.
- Market Timing: The launch coincides with an anticipated longer and more intense allergy season across the country, which is expected to exacerbate issues for nearly two-thirds of itchy dogs, significantly increasing the demand for Befrena.
- Efficacy Advantage: Befrena begins controlling allergic itch within 24 hours by neutralizing IL-31, a key cytokine, and offers a convenient 6 to 8 weeks dosing interval, greatly enhancing convenience and efficacy for veterinarians and pet owners.
- Strategic Implications: The introduction of this product not only enriches Elanco's treatment options but also strengthens its competitive position in the veterinary pharmaceuticals market, addressing the growing demand for pet health solutions.
See More
Elanco to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Elanco Animal Health will participate in a fireside chat at the Stifel 2026 Jaws & Paws Conference on May 27, featuring CEO Jeff Simmons and CFO Bob VanHimbergen, showcasing the company's leadership in animal health.
- Key Speaking Engagements: On June 2, Jeff Simmons will present at the William Blair 46th Annual Growth Stock Conference, further elaborating on the company's strategic direction and market outlook, which is expected to attract significant investor interest.
- Live Streaming and Replays: The events will feature live audio webcasts available on Elanco's investor website under the
See More
Elanco Animal Health Q1 2026 Earnings Call Insights
- Significant Growth: Elanco achieved a 10% organic constant currency revenue growth in Q1 2026, with revenues reaching $1.371 billion, exceeding market expectations and demonstrating the company's continued market share expansion in the pet health sector, thereby enhancing confidence in future growth.
- Innovation-Driven Revenue: The company's innovation products contributed $287 million in revenue during the first quarter, with the full-year innovation revenue target raised to $1.2 billion, indicating that Elanco's ongoing investment in product innovation will provide a long-term competitive advantage.
- Optimistic Financial Outlook: Elanco has raised its full-year organic constant currency growth expectation to 5% to 7%, alongside an adjusted EBITDA forecast increase to $975 million to $1.005 billion, reflecting management's confidence in future performance and strong market demand.
- Debt Management Strategy: The company has improved its year-end net leverage target to 3.0x to 3.2x, indicating a priority on managing free cash flow, while continuing to focus on debt repayment and small tuck-in acquisition opportunities to enhance financial flexibility.
See More
Elanco Raises Full Year Outlook and Innovation Targets
- Strong Financial Performance: In Q1 2026, Elanco reported total revenue of $1.371 billion, a 15% increase year-over-year, with Pet Health revenue reaching $710 million, up 12%, showcasing the company's robust performance under its innovation-led strategy.
- Innovation-Driven Growth: The successful launches of new products like Zenrelia and Credelio Quattro have driven market share gains, particularly in the Pet Health and Farm Animal segments, which achieved revenue growth of 12% and 18% respectively, indicating the company's competitive edge in the market.
- Significant EBITDA Improvement: Adjusted EBITDA for Q1 was $334 million, reflecting a 21% increase compared to the previous year, highlighting ongoing improvements in cost control and operational efficiency, which further bolster investor confidence.
- Upgraded Full-Year Guidance: Elanco has raised its full-year revenue outlook for 2026 to between $5.010 billion and $5.085 billion, anticipating benefits from favorable foreign exchange rates and continued price growth, demonstrating the company's agility in a dynamic market environment.
See More
Elanco to Announce Q1 Earnings on May 6
- Earnings Announcement Date: Elanco (ELAN) is set to announce its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.34, reflecting an 8.1% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: Analysts project Elanco's Q1 revenue to reach $1.28 billion, representing a 7.6% year-over-year increase, indicating sustained demand and strategic market expansion in the animal health sector.
- Performance Beat Record: Over the past two years, Elanco has beaten EPS and revenue estimates 88% of the time, showcasing its stable performance and management capabilities, which may bolster investor confidence in future results.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and seven downward adjustments, while revenue estimates experienced three upward revisions and two downward adjustments, reflecting mixed market perceptions regarding the company's future performance.
See More
Elanco Secures FDA Emergency Use Authorization for Screwworm Treatment
- Emergency Use Authorization: Elanco has received Emergency Use Authorization from the FDA for Negasunt Powder, allowing its use for the prevention and treatment of New World screwworm infestations, ensuring veterinarians and livestock producers have immediate access to effective treatment options should the pest be detected in the U.S.
- EPA Exemption Support: Additionally, Elanco has secured a Section 18 Emergency Exemption from the EPA for Tanidil, enabling its use in various livestock species, which will enhance the livestock industry's ability to respond to potential infestations.
- Distribution Channels: Negasunt Powder and Tanidil will be distributed through the U.S. Animal Plant Health Inspection Service (APHIS) and its National Veterinary Stockpile, ensuring timely access to necessary medications for producers to mitigate economic losses in the event of an infestation.
- Education and Prevention Measures: Elanco emphasizes the importance of self-education for producers regarding New World screwworm prevention and encourages regular livestock inspections to facilitate early detection and treatment, thereby reducing tissue damage and mortality rates.
See More
